Combined Company Will H ave Over $275 Million in Operating Capital and Trade on Nasdaq under the Ticker Symbol “KDNY” VANCOUVER, British Columbia and SEATTLE, Oct. 05, 2020 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (NASDAQ: KDNY), a clinical-stage biotechnology company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced the closing of its merger with Aduro Biotech, Inc. and $115 million priva
October 5, 2020
· 6 min read